Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Lilly donanemab flaunts strong clinical profile in data read-out, ready to compete with Leqembi if approved, says GlobalData

Following the news that Eli Lilly published full results from its TRAILBLAZER-ALZ 2 (NCT04437511) study of anti-amyloid-beta (Aβ) monoclonal antibody (mAb), donanemab, in Alzheimer’s disease (AD); Rose Joachim, Director of Neurology at GlobalData, a leading data and analytics company, offers her view: “On the heels of the US FDA’s approval of Eisai and Biogen’s Leqembi […]
Read more

China in-house R&D paves way for improved access to KRAS G12C inhibitors for NSCLC, says GlobalData

China is emerging as a key player in developing novel oncology therapies, particularly in treating non-small cell lung cancer (NSCLC). Kirsten rat sarcoma homolog (KRAS) G12C inhibitors have gained significant attention for their efficacy in targeting KRAS G12C mutations, prevalent in NSCLC. China’s robust pipeline of in-house developed therapies targeting these mutations promises future affordability […]
Read more

2022 saw decade-high immuno-oncology approvals, finds GlobalData

As oncology diagnoses increase across the globe, immuno-oncology therapies have emerged as a novel treatment category, outside of chemotherapy and radiotherapy, that can help combat aggressive forms of cancer. Against this backdrop, 2022 saw a record number of immuno-oncology approvals with 10 new innovative drugs being approved, finds GlobalData, a leading data and analytics company. […]
Read more

China success story in homegrown CAR-T therapies development continues with Fucaso approval, says GlobalData

The National Medical Products Administration (NMPA) has recently approved Innovent Biologics and IASO Bio’s CAR-T therapy equecabtagene autoleucel (Fucaso) for the treatment of relapsed and/or refractory multiple myeloma (R/R MM). It will be the first CAR-T therapy for MM patients and second one by a homegrown company in China. The approval will further boost CAR-T […]
Read more

BioCardia eyes heart failure space in Japan with CardiAMP Cell Therapy System, says GlobalData

BioCardia has recently completed the submission of CardiAMP Cell Therapy System to Japan’s Pharmaceutical and Medical Device Agency (PMDA) towards approval for the indication of ischemic heart failure (HF) with reduced ejection fraction. If approved, CardiAMP would be a minimally invasive stem cell therapy option for patients with ischemic systolic HF, says GlobalData, a leading […]
Read more

NMPA approval for first BCMA CAR-T Therapy paves way for more multiple myeloma cell therapies, says GlobalData

Approval to dramatically change CAR-T therapies landscape GlobalData forecasts Fucaso sales to reach $69 million in 2029 Manufacturing and logistical challenges may impact commercial success Nanjing Iaso Biotherapeutics and Innovent Biologics have received China National Medical Product Administration (NMPA) approval for Fucaso (equecabtagene autoleucel) as a treatment for patients with relapsed or refractory multiple myeloma […]
Read more

Diagnosed incident cases of venous thromboembolism across 7MM set to reach 1.69 million in 2032, forecasts GlobalData

The burden of diagnosed incident cases of venous thromboembolism (VTE) in the 7MM* is expected to increase at an annual growth rate (AGR) of 1.50% from 1.47 million in 2022 to 1.69 million cases in 2032, forecasts GlobalData, a leading data and analytics company. GlobalData’s latest report, “Venous Thromboembolism: Epidemiology Forecast to 2032,” estimates that […]
Read more

Eli Lilly obesity drug retatrutide trials set to challenge weight loss results seen with other GLP-1RAs, says GlobalData

Eli Lilly’s retatrutide garnered interest recently following the release of results, which set a record for percentage body weight loss in the obesity space. Retatrutide, which is currently in development for obesity, type 2 diabetes (T2D), and non-alcoholic fatty liver disease (NAFLD), is of special interest due to addressing the need for improved efficacy within […]
Read more

Amneal Parkinson’s drug IPX203 needs to compete with novel subcutaneous levodopa delivery systems post FDA CRL, says GlobalData

Following the news that Amneal Pharmaceuticals received a complete response letter (CRL) from the FDA, concerning its new drug application for IPX203 (carbidopa/levodopa) as a treatment for Parkinson’s disease (PD); Christie Wong, Neurology Analyst at GlobalData, a leading data and analytics company, offers her view: “Although levodopa has been the gold standard for patients with […]
Read more

Soliris approval for MG will allow AstraZeneca play key role in rare disease treatment ecosystem in China, says GlobalData

AstraZeneca’s Soliris (eculizumab) was approved in China in June 2023 for the treatment of adults with refractory generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody positive. MG patients in China will now finally have access to this novel targeted therapy as part of an expanded treatment algorithm. This will allow AstraZeneca to play a […]
Read more

Bad clinical practices overshadow BioXcel positive results for Igalmi in Alzheimer’s agitation, says GlobalData

Following the news that BioXcel Therapeutics announced positive top-line results from TRANQUILITY II (NCT05271552), a Phase III study of Igalmi (dexmedetomidine sublingual film) for the acute treatment of agitation episodes associated with Alzheimer’s disease (AD); Philippa Salter, Senior Neurology Analyst at GlobalData, offers her view: “Although the clinical trial met its primary endpoint for the […]
Read more

Inflammatory bowel disease treatments reach inflection point requiring active comparators, says GlobalData

At Digestive Disease Week (DDW) 2023, a comment was made following a presentation discussing the preliminary induction findings from QUASAR (NCT04033445), the Phase IIb/III trial evaluating Janssen’s guselkumab (GUS) in ulcerative colitis (UC). A member of the audience questioned the talk’s overall conclusion that GUS is a “great therapy”. This individual’s comment reflects an overarching […]
Read more

Rystiggo will need excellent marketing strategy to fully compete in myasthenia gravis space, says GlobalData

The FDA has recently approved UCB’s subcutaneous formulation of rozanolixizumab-noli, branded as Rystiggo, for use in myasthenia gravis (MG). The approval of Rystiggo comes six months after the FDA accepted UCB’s priority review application, making it the first approved treatment for MG. It is indicated for both anti-acetylcholine receptor (AChR) and anti-muscle-specific tyrosine kinase (MuSK) […]
Read more
1 … 31 32 33 34 35 … 108